Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited ...

SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was ...

With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...

The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...

Beyond the 4-week mark, both MG-ADL and Quantitative Myasthenia Gravis scores improved in the overall population and in all ...

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients on telitacicept ...

With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...

What are called autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most ...

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...